MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
78.59
+0.07
+0.09%
After Hours: 78.59 0 0.00% 16:10 07/17 EDT
OPEN
77.52
PREV CLOSE
78.52
HIGH
79.41
LOW
77.47
VOLUME
704.13K
TURNOVER
--
52 WEEK HIGH
90.87
52 WEEK LOW
43.18
MARKET CAP
6.52B
P/E (TTM)
-34.0158
1D
5D
1M
3M
1Y
5Y
1D
Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?
Simply Wall St · 5h ago
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
NASDAQ · 2d ago
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
NASDAQ · 2d ago
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
NASDAQ · 2d ago
PTC Therapeutics schedules second-quarter 2026 results webcast conference call
PUBT · 3d ago
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PR Newswire · 3d ago
PTC Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 3d ago
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130
Benzinga · 3d ago
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.